Logotype for Alpha Tau Medical Ltd

Alpha Tau Medical (DRTS) Study update summary

Event summary combining transcript, slides, and related documents.

Logotype for Alpha Tau Medical Ltd

Study update summary

16 Nov, 2026

Trial design and treatment

  • REGAIN is a prospective, open-label, single-arm study expanded from 10 to 20 patients; eight treated, with six reaching response assessment and planned 12-month follow-up.

  • Eligible patients have IDH wild-type grade 4 glioma, up to three recurrences and tumors under 3 cm; treatment uses image-guided stereotactic implantation of radium-224-loaded titanium sources.

  • Alpha DaRT uses radium-224 decay to release daughter atoms into tumors; alpha radiation acts independently of oxygen and causes double-strand DNA breaks, while particles travel 40–90 microns in tissue.

Interim efficacy and feasibility

  • Planned sources were deployed with tumor coverage in all treated patients; no unanticipated serious adverse events were reported.

  • All eight patients were alive at median follow-up of ~7 months; among six assessed, best response was five complete and one partial response, for a 100% overall response rate.

  • No recurrence was observed at treated sites; one progression occurred at a distant location. Response confirmation remains ongoing as additional scans are collected.

  • One grade 3 serious adverse event, a seizure with Todd's paralysis, resolved after rehabilitation and steroids; the patient returned to baseline.

  • Suspected necrosis or treatment changes were under evaluation in two patients and were asymptomatic; clinicians noted that later scans are needed to distinguish treatment effects from progression.

Follow-up and development plans

  • Enrollment is expanding across multiple sites, including NYU and Barrow; an additional interim GBM data update is expected when the first five patients complete six months, targeted for Q1 2027.

  • The study uses MRI and RANO for response assessment; amino acid PET is used at Ohio State to help evaluate ambiguous lesions, but is not standard across the trial.

  • FDA discussions continue on data maturity and a potential regulatory pathway; the study has Breakthrough Device Designation and is part of the Total Product Life Cycle Advisory Program.

  • Management expects Hudson, New Hampshire manufacturing capacity for commercial quantities by FDA approval; a focused launch strategy would target high-volume U.S. centers.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Alpha Tau Medical